NutraceuticalD

Tocotrienol

Tocotrienol (Vitamin E complex)

One small Malaysian RCT showed a hair-count increase. Never replicated. Used by Nutrafol to justify its tocotrienol content.

DEvidence grade
1Claims evaluated
1Key human trials
2 / 5Strength for hair
Mechanism & evidence strength

How Tocotrienol works — and how well we know it

Mechanism of action

Tocotrienols are members of the vitamin E family with stronger antioxidant activity than alpha-tocopherol. Hypothesized to reduce oxidative stress in scalp tissue, which has been correlated with AGA in some studies.

Lipid peroxidation in scalp tissue
Route

oral

Typical dose

100 mg/day mixed tocotrienol capsules (studied dose).

Regulatory status

Available as a dietary supplement. Distinct from the more common alpha-tocopherol form of vitamin E.

Best for

Speculative. As a low-risk add-on for users already on proven therapy who want a possible antioxidant adjunct.

Evidence distribution across 1 claims

In Silico
In Vitro
In Vivo
Ex Vivo
Open-Label
RCT1

Why the grade is D. One small Malaysian RCT (n=21 active / n=17 placebo) showed a 34% mean hair-count increase. Never independently replicated. Mechanism is plausible but indirect.

Evidence breakdown

Every claim, traced back to its source

We took every major claim made about Tocotrienol and matched it to the specific experimental model behind it. Click a claim to see the model, the finding, and our assessment of how much weight it deserves.

1 claims · evidence-by-evidence breakdown

1
RCTWeight: Low
Beoy 2010: 100 mg/day mixed tocotrienol increased hair count vs. placebo over 8 months
Single small RCT with an unusually large effect size that has never been independently replicated. Treat as hypothesis-generating only.
The experimental model

Randomized, double-blind, placebo-controlled trial, n=38 (21 active, 17 placebo), 8 months. Adult volunteers with mild AGA. Active arm received 100 mg/day mixed tocotrienol; placebo received soy oil capsules.

The finding

Mean hair count in the active arm increased by 34.5% vs. baseline; placebo arm decreased by 0.1%. Difference statistically significant.

Our assessment

The only RCT of tocotrienol for AGA. Small sample, single site, never replicated independently. The effect size is implausibly large for a non-androgen-targeted intervention — larger than minoxidil in similar populations. Either tocotrienol is more effective than minoxidil for AGA (unlikely on mechanism) or there's a methodological issue with the trial. Until replication, this is interesting but should not drive treatment decisions.

Citations
Open questions

What's still missing from the science

  • Any independent replication of the Beoy 2010 trial.
  • A larger (>100) multi-center RCT.
  • Direct comparison to minoxidil or finasteride.
  • Mechanism-of-action studies in human follicles.
Bottom line

Our verdict on Tocotrienol

Promising single trial, never replicated
Tocotrienol got its single positive RCT in 2010 from a small Malaysian study with an effect size larger than minoxidil's. Over 15 years later, no independent group has replicated it. The mechanism (antioxidant reduction of scalp oxidative stress) is plausible but indirect — it doesn't address the androgen-driven cause of AGA. The cost is low and the safety profile is benign, so as an add-on to proven therapy it's defensible. As a standalone treatment, the evidence is one trial.
One small trial with a suspiciously large effect, never replicated. Cheap and safe enough to use as an add-on if you want; not strong enough to use as a foundation.
At Anagen

Not in our formulary yet

We don't carry this ingredient. We only formulate around actives where the evidence — and the safety profile — is strong enough to recommend with confidence. As the data matures, we may revisit.

Tocotrienol: Evidence-Based Hair Loss Review | Anagen